Core Insights - Niagen Bioscience Inc. reported strong financial performance for 2025, with net revenue of $129.4 million, reflecting a 30% year-over-year growth, and a net income of $17.4 million [5][25][30] - The company is well-positioned for 2026, despite increased competition in the NAD market, and continues to lead in NAD science with significant research backing [6][13] - The company has secured a patent for NIAGEN Plus, which will expand its product offerings into intravenous and injectable formulations, and plans to launch at-home injection kits in 2026 [8][9] Financial Performance - In Q4 2025, revenue reached $33.8 million, a 16% increase from the previous year, driven primarily by e-commerce sales [5][27] - Gross margin improved to 64.3% for the full year, indicating enhanced operational efficiency [25] - Selling and marketing expenses were 30.8% of sales in Q4, reflecting targeted investments in brand awareness [29] Research and Development - Niagen Bioscience Inc. remains the global leader in NAD science, with 29 studies published since the last earnings call, including clinical studies demonstrating the benefits of nicotinamide riboside (NR) [6][15] - Notable studies include findings that NR supplementation can slow aging and improve fatigue, sleep quality, and cognitive function [7][16][20] - The company is focusing on the therapeutic potential of NR in neurodegenerative diseases, including ongoing collaborations to explore its preventive effects in Parkinson's disease [18][57] Product Development and Market Expansion - The company plans to expand its presence in the beauty and cosmetics market, following the successful launch of Tru Niagen in beauty [9][46] - Niagen Plus will be introduced in over 1,200 health clinics, with plans to partner with telehealth providers for distribution [8][9] - The company is also exploring new retail channels and international markets, particularly in Asia and the EU [46] Legal and Regulatory Environment - Niagen Bioscience Inc. is currently involved in litigation against the FDA regarding the marketing of NMN as a dietary supplement, believing it has a strong case [10][55] - The company has acquired patents for multiple NR salt forms, enhancing its intellectual property portfolio and market position [11]

Financial Data and Key Metrics Changes - In Q4 2025, revenue was $33.8 million, a 16% year-over-year increase, with net income of $4.1 million [10] - For the full year 2025, net revenue reached $129.4 million, representing a 30% growth year-over-year, and net income was $17.4 million [10][38] - The company ended the year with $64.8 million in cash and no debt, indicating strong financial stability [10][43] Business Line Data and Key Metrics Changes - Revenue from the Tru Niagen product line grew by 21% to $27.5 million, driven primarily by e-commerce sales of $20.2 million, which increased by 17% [40] - Niagen ingredient revenue was $5.6 million, up 5% year-over-year, with food-grade sales at $4.7 million and pharma-grade sales at $900,000 [40] - Revenue from B2B distribution partners totaled $7.3 million, supported by strategic partnerships [41] Market Data and Key Metrics Changes - The company is expanding its presence in over 1,200 health clinics and plans to launch at-home Niagen Plus injection kits through a telehealth platform [15] - The company anticipates continued growth in the Asia-Pacific markets and selective retail channels [66] Company Strategy and Development Direction - The company aims to focus on NAD science and intellectual property while exiting non-core activities, as evidenced by the sale of the ChromaDex Reference Standards business [21][45] - Plans include expanding into the beauty cosmetics market and launching new products, including topical products featuring Niagen [16][66] - The company is committed to maintaining its leadership in NAD science and enhancing its product offerings through strategic R&D investments [20][48] Management's Comments on Operating Environment and Future Outlook - Management acknowledged increased competition in the NAD space but emphasized the company's strong foundation and expertise [11] - The company expects to achieve 10%-15% growth in net sales for 2026, with a slight improvement in gross margin [45][46] - Management expressed confidence in the company's ability to deliver value to stakeholders and maintain its market position [48] Other Important Information - The company secured a patent for intravenous and injectable formulations of NR, indicating potential for new product development [15] - Ongoing litigation against the FDA regarding NMN products is expected to have minimal impact on legal expenses [76] Q&A Session Summary Question: Discussion on injections and telehealth platform - Management confirmed that initially, there will be one SKU for injections, targeting the biohacker community and those interested in longevity interventions [53] Question: Guidance for 2026 - Management indicated that the guidance is conservative, reflecting a cautious approach to revenue projections [58] Question: Growth drivers for 2026 - Management expects growth from existing products, new distribution channels, and increased brand awareness [66] Question: Lawsuit against the FDA - Management believes the case will likely result in a summary judgment and is optimistic about a favorable outcome [76] Question: Share repurchase strategy - Management plans to utilize the remaining $9.75 million of the buyback program, viewing it as a good investment at current prices [79]

Financial Data and Key Metrics Changes - In Q4 2025, revenue was $33.8 million, a 16% year-over-year increase, with net income of $4.1 million [6][24] - For the full year 2025, net revenue reached $129.4 million, representing a 30% growth year-over-year, and net income was $17.4 million [7][26] - The company ended the year with $64.8 million in cash and no debt, reinforcing financial stability [30] Business Line Data and Key Metrics Changes - Revenue from Tru Niagen grew by 21% to $27.5 million, primarily driven by e-commerce sales of $20.2 million, which increased by 17% [26][28] - Niagen ingredient revenue was $5.6 million, up 5% year-over-year, with food-grade sales at $4.7 million and pharma-grade sales at $900,000 [27] - Revenue from B2B distribution partners totaled $7.3 million, supported by strategic partnerships [27] Market Data and Key Metrics Changes - The company is expanding its presence in over 1,200 health clinics and plans to launch at-home injection kits through a telehealth platform [10] - The market for NAD products is growing, with increased competition, particularly from NMN products [8][11] Company Strategy and Development Direction - The company aims to build on its strong foundation in NAD science, focusing on expanding its product offerings and market presence [8][10] - Plans include launching Niagen Plus branded at-home injection kits and expanding into the beauty cosmetics market [10][11] - The company is pursuing litigation against the FDA regarding NMN products, believing it has a strong case [11][62] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in delivering strong performance in 2026 despite challenges from increased competition [8] - The company anticipates 10%-15% growth in net sales for 2026, with a slight improvement in gross margin [32][33] - Management emphasized the importance of scientific integrity and continued investment in R&D to support innovation [29] Other Important Information - The company divested its ChromaDex Reference Standards business to streamline operations and focus on core activities [13][32] - A recent patent was secured for NR and derivatives in intravenous and injectable formulations, indicating potential growth opportunities [10] Q&A Session Summary Question: Discussion on injections and SKUs - The company plans to initially offer one SKU for injections, targeting the biohacker community and expanding to other audiences later [40] Question: Guidance for the year - Management indicated that guidance is conservative, reflecting a cautious approach to revenue projections [43] Question: Growth drivers for the year - Growth is expected from existing products, new distribution channels, and increased awareness of Niagen and Tru Niagen [50] Question: Legal proceedings against the FDA - Management believes the lawsuit will not significantly impact costs and expects a summary judgment [62] Question: Share repurchase strategy - The company plans to utilize its $10 million buyback program more actively in the future [65]

Financial Data and Key Metrics Changes - In Q4 2025, revenue was $33.8 million, a 16% year-over-year increase, with net income of $4.1 million [5][21] - For the full year 2025, net revenue reached $129.4 million, representing a 30% growth year-over-year, and net income was $17.4 million compared to $8.6 million in 2024 [5][23] - The company ended the year with $64.8 million in cash and no debt, reinforcing financial stability [5][26] Business Line Data and Key Metrics Changes - Revenue from Tru Niagen grew by 21% to $27.5 million, primarily driven by e-commerce sales of $20.2 million, up 17% [23][24] - Niagen ingredient revenue was $5.6 million, a 5% increase year-over-year, with food-grade sales at $4.7 million and pharma-grade sales at $900,000 [24] - Revenue from B2B distribution partners totaled $7.3 million, supported by strategic partnerships [24] Market Data and Key Metrics Changes - The company is expanding its presence in over 1,200 health clinics and plans to launch at-home injection kits through a telehealth platform in 2026 [8] - The company anticipates continued growth in Asia-Pacific markets and selective retail channels [47] Company Strategy and Development Direction - The company aims to focus on NAD science and has divested non-core activities, such as the sale of the ChromaDex Reference Standards business [11][29] - Plans include launching Niagen Plus branded at-home injection kits and expanding into the beauty cosmetics market [8][9] - The company is pursuing litigation against the FDA regarding NMN products, believing it has a strong case [9][56] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in delivering strong performance in 2026 despite increased competition in the NAD space [6][31] - The company expects 10%-15% growth in net sales for 2026, with a slight improvement in gross margin due to supply chain efficiencies [29][30] - Management emphasized the importance of scientific integrity and continued investment in R&D to support innovation [25][30] Other Important Information - The company secured a patent for intravenous and injectable formulations of NR, indicating potential for new product offerings [8] - Management highlighted the therapeutic potential of NR supplementation based on recent studies, including benefits for long COVID and cognitive health [14][16] Q&A Session Summary Question: Discussion on injections and SKUs - The company plans to start with one SKU for injections, targeting the biohacker community and those interested in longevity interventions [35][36] Question: Guidance for the year - Management indicated that guidance is conservative, reflecting a cautious approach to revenue projections [40] Question: Growth drivers for the year - Growth is expected from existing products, new IV and beauty products, and expanded distribution channels [46][47] Question: Lawsuit against the FDA - Management believes the lawsuit will not significantly impact costs and anticipates a summary judgment [56][57] Question: Share repurchase strategy - The company plans to utilize its $10 million buyback program more actively in the future [60]

Q4 2025 Earnings Presentation February 18, 2026 Xandra Velzeboer Netherlands Short Track Speed Skating Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws, including any projections of earnings, re ...

Summary of Niagen Bioscience FY Conference Call Company Overview - Niagen Bioscience, formerly known as ChromaDex, focuses on nicotinamide riboside (NR), a precursor to the coenzyme NAD (nicotinamide adenine dinucleotide) [2][3] - The company has over 100 patents related to NAD precursors and has conducted 41 clinical studies and over 100 preclinical studies on Niagen [4] Core Product and Market Position - Niagen is positioned as the leading product in the NAD supplement space, with claims of improving cellular resilience and healthspan, particularly in aging populations [3][10] - The company has diversified its offerings, selling Niagen as a dietary supplement, a B2B ingredient, and as an injectable product [5][13] Financial Performance - Niagen Bioscience reported approximately $125 million in revenue and $20 million in net income over the last 12 months, with a strong balance sheet showing nearly $65 million in cash and no debt [20] - The company operates conservatively, focusing on maintaining a strong cash position and exploring growth opportunities [28] Growth Opportunities - The NAD IV market is rapidly growing, potentially surpassing the supplement market, with initial retail sales estimated between $50-$100 million in the first year [24][23] - Plans to launch a telehealth business for at-home injections are expected to cater to the growing interest in self-administered health products [15] Research and Development - Niagen Bioscience emphasizes R&D, investing significantly in understanding its products and their effects, with a commitment to quality science [18] - The company is exploring applications in orphan diseases, particularly those that cause rapid aging in children, with promising results from clinical studies [16] Skincare Market Potential - The company is pursuing opportunities in the skincare market, leveraging niacinamide, which elevates NAD but is less effective than NR [17] - Discussions with major global skincare companies are ongoing, with expectations for announcements in 2026 [18] Strategic Partnerships - Niagen has formed partnerships with networks of healthcare practitioners to educate consumers and promote its products [26] - The company aims to differentiate itself through scientific credibility and informed marketing strategies [27] Market Challenges - The company faces challenges from competitors and infringers in the NAD space, which can impact sales and market perception [22] - The stock has shown volatility, attributed to external market factors rather than company performance [20] Conclusion - Niagen Bioscience is well-positioned in the growing NAD market, with a strong financial foundation and diverse product offerings. The company is focused on expanding its market presence through innovative products, strategic partnerships, and a commitment to research and development [20][28]

Core Viewpoint - Niagen Bioscience, Inc. has partnered with Truemed to allow qualified customers to purchase its leading NAD+ supplement, Tru Niagen, using Health Savings Account (HSA) and Flexible Spending Account (FSA) funds, enhancing accessibility for consumers seeking nutritional support for cellular health [1][2][3] Group 1: Partnership and Accessibility - The partnership with Truemed enables a streamlined checkout experience for customers using HSA/FSA funds to purchase Tru Niagen [2][4] - Eligible customers can obtain a Letter of Medical Necessity (LMN) from a licensed provider to support their HSA/FSA eligibility [4][7] Group 2: Product Information - Tru Niagen is recognized as the number one NAD+ supplement in the United States, featuring Niagen, a patented form of nicotinamide riboside (NR), which is a highly efficient NAD+ booster [3][11] - The product is supported by over 40 peer-reviewed human clinical studies and more than 500 published scientific papers, highlighting its rigorous quality and scientific standards [3][11] Group 3: Company Background - Niagen Bioscience is a leader in NAD+ science and healthy-aging research, dedicated to advancing healthspan through innovative NAD+-boosting solutions [8][9] - The company collaborates with renowned scientists and research institutions globally to explore the potential of NAD+, which is crucial for cellular health and declines with age [9][10]

Core Viewpoint - Niagen Bioscience, Inc. has launched Tru Niagen® Beauty, the first beauty supplement in the US featuring Niagen, a patented form of nicotinamide riboside (NR), which is recognized as the most efficient and effective NAD+ booster available [1] Company Summary - Niagen Bioscience, Inc. is positioned as a global authority on NAD+ with a focus on healthy aging science [1] - The launch of Tru Niagen Beauty signifies an expansion of the company's leadership in NAD+ skincare science [1]

Financial Data and Key Metrics Changes - The company reported a record revenue of $31.1 million for Q2 2025, representing a 37% increase year over year, and a net income of $3.6 million compared to virtually breakeven a year ago [7][20]. - The cash position at the end of the quarter was $60.5 million with no debt [24]. - Gross margin improved to 65%, up from 60.2% a year ago, driven by lower cost inventory and higher e-commerce sales [22]. Business Line Data and Key Metrics Changes - E-commerce business generated $18.1 million in net sales, a 39% increase year over year [7][21]. - The food grade and pharmaceutical grade Niagen ingredient business grew 135% year over year, with revenue of $7.4 million [8][21]. - TRU NIAGEN revenue increased by 22% to $22.7 million, primarily driven by e-commerce revenues [21]. Market Data and Key Metrics Changes - The company is expanding its presence in wellness clinics, onboarding over 800 clinics nationwide to offer the Niagen Plus product line [8]. - The partnership with Watsons in Hong Kong is contributing to steady revenues, with plans for joint marketing efforts to grow brand presence [22]. Company Strategy and Development Direction - The company is focusing on expanding its Niagen Plus product line and exploring telehealth functionality on its website [9][8]. - A worldwide exclusive license agreement was signed with Haukeland University Hospital for the development of nicotinamide riboside as a potential therapy for Parkinson's disease [17]. - The company aims to maintain its position as the gold standard in NAD science and is committed to scientific innovation in the dietary supplement industry [14][20]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory and strategic goals, highlighting the strong demand for NAD products [19][20]. - The company raised its revenue growth expectation for the full year from 20%-25% to a range of 22%-27% year over year [27]. - Management noted ongoing scrutiny from California regarding outsourcing facility practices but remains optimistic about the partnership with Wells Pharmacy Network [9][10]. Other Important Information - The company has been featured in major media outlets and events, increasing awareness of its products [10][12]. - There is ongoing research into the effects of NAD supplementation on long COVID and fertility, with studies expected to be published soon [15][16][51]. Q&A Session Summary Question: Regarding the initiative for Parkinson's disease - Management indicated that if the NOPARC trial results are positive, they may pivot to nicotinamide riboside triacetate for FDA approval in the U.S. [30][32]. Question: Volume and pricing for NIAGEN IV in clinics - Management noted that while clinics are currently charging high prices for IV experiences, they believe prices need to come down to increase accessibility and volume [36][39]. Question: Steps for treating long COVID - The key milestone to watch is the publication of the Harvard study on NAD supplementation for long COVID, which could lead to a marketing campaign if results are positive [49][54].

Financial Data and Key Metrics Changes - In Q1 2025, the company reported revenues of $30,500,000, representing a 38% year-over-year increase [8][18] - Net income for the quarter was $5,100,000, compared to a net loss of $500,000 in Q1 2024 [21] - Cash generated from operations was $7,900,000, a significant increase from $300,000 in the same period last year [22] - The company ended the quarter with $55,600,000 in cash and no debt, maintaining strong liquidity [21] Business Line Data and Key Metrics Changes - E-commerce sales grew by 31% year-over-year, contributing significantly to revenue growth [9][18] - The food grade and pharmaceutical grade Niagen ingredient business saw a 95% increase, reaching $8,000,000 [9][18] - Gross margin improved to 63.4%, up from 60.7% a year ago, driven by a favorable product mix and cost savings [18] Market Data and Key Metrics Changes - The demand for NAD-boosting products is surging, with increasing consumer awareness of Niagen as a trusted solution [12][14] - The company aims to expand its presence in clinics, targeting 1,000 clinics by the end of 2025, with a potential addressable market of 2,000 to 3,000 clinics [42] Company Strategy and Development Direction - The company is focused on reinforcing Niagen as the leading NAD-boosting solution, aligning its brand with its mission of promoting healthy aging [15][16] - The pharmaceutical application of nicotinamide riboside (NR) is a key strategic initiative, with ongoing studies and FDA dialogues [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustained momentum across e-commerce and ingredient businesses, raising the full-year growth outlook to 20% to 25% [22][23] - The company is committed to operational discipline and efficiency, with a focus on long-term profitability [26] Other Important Information - The company announced a new composition of matter patent granted in March, broadening its patent portfolio [11] - Management highlighted the importance of maintaining integrity and scientific rigor in the NAD supplement market [13][14] Q&A Session Summary Question: What are the emerging tailwinds for NIAGEN IV product adoption? - Management noted significant interest from clinics and physicians, with 600 clinics currently offering NIAGEN IV and expectations for increased sales [28][32] Question: Are there new promotional strategies for e-commerce? - Management indicated a focus on profitability and efficiency, with plans to increase presence on platforms like TikTok and engage with influencers [35][37] Question: What is the potential market for NIAGEN plus? - Management aims to onboard 1,000 clinics by year-end, with a larger addressable market identified [42] Question: What is the status of the injectable NIAGEN plus? - Management confirmed that an at-home version is in development, expected to be available by Q4 2025 [72][73] Question: What is the status of the FDA discussions regarding ataxia telangiectasia? - Active discussions are ongoing with the FDA, with a pre-IND submission made and feedback received [90][91]